Revision of criteria for the diagnosis and evaluation of response to therapy in multiple myeloma


Authors: V. Maisnar 1,3;  R. Hájek 2,3
Authors‘ workplace: II. interní klinika – Oddělení klinické hematologie, LF UK a FN Hradec Králové 1;  Interní hemato-onkologická klinika, LF MU a FN Brno-Bohunice 2;  Česká myelomová skupina 3
Published in: Transfuze Hematol. dnes,14, 2008, No. 3, p. 119-123.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The International Myeloma Working Group has reviewed their criteria for diagnosis and classification and also response criteria for multiple myeloma with the aim of producing simple, easily used definitions based on routinely available investigations. The use of these criteria will facilitate comparison of therapeutic trial data in the future.

Key words:
monoclonal gammopathies, multiple myeloma, diagnosis, classification, response criteria


Sources

1. Adam Z, Gregora E, Hájek R, et al. Diagnostika a léčba mnohočetného myelomu: Doporučení České myelomové skupiny a Myelomové sekce České hematologické společnosti pro diagnostiku a léčbu mnohočetného myelomu. Trans. Hemat. dnes 2005; 11 (Suppl. 1): 3–51.

2. Attal M, Harousseau J-L, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 26: 2495–2502.

3. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol 2006; 24: 929–936.

4. Durie BGM. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005; 6: 181–190.

5. Cavo M, Zamagni E, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for mulitple myeloma. Blood 2005; 106: 35–39.

6. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762.

7. Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001; 47: 673–680.

8. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348–354.

9. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chains ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812–817.

10. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

11. D’Sa S, Abildgaard N, Tighe J, et al. Guidelines for the use of imaging in the management of myeloma. Br J Haematol 2007; 137: 49–63.

12. Durie BGM. The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system. Eur J Cancer 2006; 42: 1539–1543.

13. Baur A, Stabler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical stating system of Durie and Salmon? Cancer 2002; 95: 1334–1345.

14. Mysliveček M, Bačovský J, Kamínek M, et al. Scintigrafie pomocí 99mTc-MIBI v diagnostice mnohočetného myelomu: senzitivní ukazatel biologické aktivity choroby. Klin Onkol 2004; 17: 13–17.

15. Durie BGM, Waxman AD, DęAngeloa A, William CM. Whole body F-FDG PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457–1463.

16. Avet-Loiseau H. Genetics of multiple myeloma. Hematology 2005; 1: 206–210.

17. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010.

18. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854.

19. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

20. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. A review. Br J Haematol 2006; 134: 573–589.

21. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.

22. Durie BGM, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4: 379–398.

23. Stewart AK, Bergsagel PL, Greipp PR, et al. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007; 21: 529–534.

Labels
Haematology Internal medicine Clinical oncology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account